Patients with a triple-positive mutation profile of EGFR, TP53, and RB1 exhibited a 6-fold augmented susceptibility to SCLC conversion compared with patients without mutations in TP53 and RB1 (39, 40). This evidence concerns the gene TP53 and small cell lung carcinoma.